Neuroblastoma is a paediatric cancer of the sympathetic nervous system and the most
common solid tumour of infancy, contributing to 15% of paediatric oncology deaths. Current …

Despite advances in cancer therapeutics, particularly in the area of immuno-oncology,
successful treatment of neuroblastoma (NB) remains a challenge. NB is the most common …

Patient-derived preclinical models are now a core component of cancer research and have
the ability to drastically improve the predictive power of preclinical therapeutic studies …

Neuroblastoma is a childhood cancer derived from the sympathetic nervous system. High-
risk neuroblastoma patients have a poor overall survival and account for~ 15% of childhood …

Neuroblastoma is the most common pediatric abdominal solid tumor. This aggressive
embryonal malignancy of neural crest origin has a peak age of onset of 22 months, and …

After leukemia, tumors of the brain and spine are the second most common form of cancer in
children. Despite advances in treatment, brain tumors remain a leading cause of death in …

In the quest to advance neuroblastoma therapeutics, there is a need to have a deeper
understanding of the tumor microenvironment (TME). From extracellular matrix proteins to …

The potential of tumor three-dimensional (3D) in vitro models for the validation of existing or
novel anti-cancer therapies has been largely recognized. During the last decade, diverse in …

Background Preclinical models of pediatric cancers are essential for testing new
chemotherapeutic combinations for clinical trials. The most widely used genetic model for …

Neuroblastoma is the most common extracranial solid tumor in children, accounting for 15%
of overall pediatric cancer deaths. The native tumor tissue is a complex three-dimensional …